Lupin Ltd.

Financial

	Lupin	Zydus Lifesciences	Dr. Reddy's Lab
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	441.0 .	486.0 .	361.0 .
Number of ANDA's Approved By USFDA	340.0 .	421.0 .	288.0 .
Domestic Sales Growth - YoY	8.0 %	8.4 %	11.1 %
US DMF Filings	157.0 .	142.0 .	n/a
R&D as a % of Total Sales	9.6 %	8.1 %	8.5 %
Financials
5 yr Average ROE	2.19 %	16.96 %	14.9 %
5yr average Equity Multiplier	1.79	1.66	1.41
5yr Average Asset Turnover Ratio	0.72	0.65	0.77
5yr Avg Net Profit Margin	1.82 %	16.78 %	14.03 %
Price to Book	5.3	3.74	3.05
P/E	27.77	19.78	18.07
5yr Avg Cash Conversion Cycle	-70.43 Days	-68.16 Days	64.1 Days
Inventory Days	51.95 Days	44.51 Days	75.39 Days
Days Receivable	52.75 Days	46.37 Days	99.54 Days
Days Payable	155.88 Days	164.0 Days	102.35 Days
5yr Average Interest Coverage Ratio	3.96	24.75	34.06
5yr Avg ROCE	8.04 %	17.68 %	19.83 %
5yr Avg Operating Profit Margin	12.57 %	22.37 %	21.19 %
5 yr average Debt to Equity	0.34	0.3	0.12
5yr CAGR Net Profit	n/a	26.82 %	22.45 %
5yr Average Return on Assets	1.4 %	10.66 %	10.71 %
Shareholdings
Promoter Holding	46.92 %	74.99 %	26.64 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.14 %	0.11 %	-0.08 %
Change in Mutual Fund Holding (3 Yrs)	1.83 %	0.81 %	-1.23 %

Business

	Lupin	Zydus Lifesciences	Dr. Reddy's Lab
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 Wellness 0 Animal Health 0 EMB Formulations 0 India Formulations 0 US Formulations 0 Proprietary Products 0 Global Generics 0 0	Product Wise Break-Up Emerging Market 0 Proprietary Products 0 0 US Formulations 47.0 Alliance 2.0 India 0 USA 0 Wellness 10.0 Custom Synthesis 0 NCD 0 Advanced Markets Formulations 0 India Formulations 28.0 Animal Health 0 Developed Markets 0 Global Generics 0 Active Pharmaceutical Ingredient (API) 0 EMB Formulations 0 Generic FDF 0 Emerging Markets 0 Europe Formulatios 0 Others 13.0	Product Wise Break-Up Emerging Market 0 Proprietary 0.17 Pharmaceutical 13.52 US Formulations 0 Alliances 0 India 0 USA 0 Wellness 0 Custom Synthesis 0 NCD 0 Advanced Markets Formulations 0 India Formulations 0 Animal Health 0 Developed Markets 0 Formulations 86.31 Active Pharmaceutical Ingredient (API) 0 EMB Formulations 0 Generic FDF 0 Emerging Markets 0 Europe Formulatios 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 99.44 Research Services & Sale of IP`s 0 Consumer Products 0 Others 0.56	Segment Break-Up OTC 9.35 Pharmaceuticals 90.65 Research Services & Sale of IP`s 0	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Cardiac Science 24.0 Anti - Diabetes 22.0 Respiratory Systems 14.0 Gastro Intestinal 7.0 Gynecology 6.0 Anti-Infective 6.0 Vitamins / Minerals / Nutrients 5.0 Anti-Tuberculosis 4.0 Central Nervous System (CNS) 4.0 Pain Management 3.0 Others 5.0	-	-
Location Wise Break-Up	Location Wise Break-Up USA 36.0 India 34.0 Developed Markets 13.0 EMEA 11.0 API 5.0 Japan 0 Russia 0 Others 1.0	Location Wise Break-Up USA 44.89 EMEA 0 Russia 0 India 41.0 API 0 Japan 0 Developed Markets 0 Others 14.11	Location Wise Break-Up USA 48.56 EMEA 0 Russia 7.99 India 17.36 API 0 Japan 0 Developed Markets 0 Others 26.09
Acute vs Chronic	Acute vs Chronic Acute 66.0 Chronic 34.0	-	-

Lupin Ltd.

SIGN UP FOR FREE